Landscape of Preterm Birth Therapeutics and a Path Forward
Open Access
- 29 June 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13), 2912
- https://doi.org/10.3390/jcm10132912
Abstract
Preterm birth (PTB) remains the leading cause of infant morbidity and mortality. Despite 50 years of research, therapeutic options are limited and many lack clear efficacy. Tocolytic agents are drugs that briefly delay PTB, typically to allow antenatal corticosteroid administration for accelerating fetal lung maturity or to transfer patients to high-level care facilities. Globally, there is an unmet need for better tocolytic agents, particularly in low- and middle-income countries. Although most tocolytics, such as betamimetics and indomethacin, suppress downstream mediators of the parturition pathway, newer therapeutics are being designed to selectively target inflammatory checkpoints with the goal of providing broader and more effective tocolysis. However, the relatively small market for new PTB therapeutics and formidable regulatory hurdles have led to minimal pharmaceutical interest and a stagnant drug pipeline. In this review, we present the current landscape of PTB therapeutics, assessing the history of drug development, mechanisms of action, adverse effects, and the updated literature on drug efficacy. We also review the regulatory hurdles and other obstacles impairing novel tocolytic development. Ultimately, we present possible steps to expedite drug development and meet the growing need for effective preterm birth therapeutics.Funding Information
- National Institute of Allergy and Infectious Diseases (AI133976, AI145890, AI143265, HD098713, HD001264)
- National Health and Medical Research Council (APP1162684, APP1113847)
- Canadian Institutes of Health Research (FDN-143262, 168858)
- March of Dimes Foundation (MOD-6-FY17-647)
- Burroughs Wellcome Fund (1013759)
This publication has 293 references indexed in Scilit:
- Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic CombinationsPharmaceuticals, 2013
- The Evidence Regarding Maintenance TocolysisObstetrics and Gynecology International, 2013
- Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient dataAmerican Journal of Obstetrics and Gynecology, 2012
- Injection-site reactions upon Kineret (anakinra) administration: experiences and explanationsRheumatology International, 2011
- Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trialUltrasound in Obstetrics & Gynecology, 2011
- Nifedipine in the management of preterm labor: a systematic review and metaanalysisAmerican Journal of Obstetrics and Gynecology, 2011
- Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicleAmerican Journal of Obstetrics and Gynecology, 2010
- A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral PalsyThe New England Journal of Medicine, 2008
- Epidemiology and causes of preterm birthThe Lancet, 2008
- Vaginal indicators of amniotic fluid infection in preterm laborObstetrics & Gynecology, 2001